Akcea Therapeutics, Inc.: 10-Q filed 2017-11-07
What Akcea Therapeutics, Inc. reported in its quarterly report filed 2017-11-07 (fiscal Q3 2017): 30 published measures, 82 facts as tagged in accession 0001662524-17-000005.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-11-07
- Fiscal period
- fiscal Q3 2017
- Accession
- 0001662524-17-000005 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Akcea Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 289,349,000 | USD | |
| At 2016-12-31 | 10,684,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 91,506,000 | USD | |
| At 2016-12-31 | 28,431,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 197,843,000 | USD | |
| At 2016-12-31 | -17,747,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 110,366,000 | USD | |
| At 2016-12-31 | 7,857,000 | USD | |
| At 2016-09-30 | 17,526,000 | USD | |
| At 2015-12-31 | 29,389,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -14,094,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -86,390,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -19,809,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -49,380,000 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | -11,672,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -3,806,000 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 9,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 58,000 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 13,449,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 37,173,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 0 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 0 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 290,381,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -880,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | -176,200,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -7,177,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | -261,052,000 | USD | |
| At 2016-12-31 | -174,662,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 59,173,938 | shares | 92 |
| 2017-01-01 to 2017-09-30 | 39,091,956 | shares | 273 |
| 2016-07-01 to 2016-09-30 | 28,884,540 | shares | 92 |
| 2016-01-01 to 2016-09-30 | 28,884,540 | shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 2,066,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 2,066,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 0 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 0 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 104,000 | USD | |
| At 2016-12-31 | 177,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 11,814,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 7,683,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -12,564,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -83,711,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -19,902,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -49,650,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 287,880,000 | USD | |
| At 2016-12-31 | 9,066,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 73,457,000 | USD | |
| At 2016-12-31 | 28,410,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 2,012,000 | USD | |
| At 2016-12-31 | 476,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 26,013,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 120,884,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 19,902,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 49,650,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 66,541,629 | shares | |
| At 2016-12-31 | 0 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | -222,000 | USD | |
| At 2016-12-31 | -21,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 114,000 | USD | |
| At 2016-12-31 | 100,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 3,452,000 | USD | |
| At 2016-12-31 | 1,041,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -12,028,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -84,324,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -19,809,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -49,380,000 | USD | 274 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -14,232,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -86,591,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -19,840,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -49,328,000 | USD | 274 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -15,885,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -106,490,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | -19,809,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -49,380,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 8,373,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 19,963,000 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 2,897,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 9,911,000 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 82,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 5,000 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 897,000 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -43,000 | USD | 274 |
Inspect the source
- Entity
- Akcea Therapeutics, Inc. / CIK 0001662524
- Captured
- SEC response SHA-256
0fb68dd31a80a5577a688080a1173e8399eaef6ca91145d82e51c2723949e906
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001662524.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))